BiotechTube

DT5aP-IPV-Hib 5-component Pertussis vaccine + DT3aP-HBs-IPV

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infant

Conditions

Infant, Healthy

Trial Timeline

Sep 1, 2006 → Jul 1, 2008

NCT ID
NCT00355654

About DT5aP-IPV-Hib 5-component Pertussis vaccine + DT3aP-HBs-IPV

DT5aP-IPV-Hib 5-component Pertussis vaccine + DT3aP-HBs-IPV is a phase 3 stage product being developed by Sanofi for Infant. The current trial status is completed. This product is registered under clinical trial identifier NCT00355654. Target conditions include Infant, Healthy.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00355654Phase 3Completed

Competing Products

20 competing products in Infant

See all competitors
ProductCompanyStageHype Score
TSHA-101Taysha Gene TherapiesPhase 1/2
36
somatropinEli LillyPhase 3
77
Placebo + CisaprideJohnson & JohnsonApproved
85
RotaTeq (V260) + IPVMerckPhase 3
77
recombinant somatropinMerckPre-clinical
23
Recombinant human growth hormone (r-hGH)MerckPhase 3
77
MAS825 + PlaceboNovartisPhase 2
52
epoetin beta + epoetin betaRochePre-clinical
23
Genotropin (PN-180,307) Somatropin + Control-no treatmentPfizerPhase 3
76
Prevenar (13v)PfizerPre-clinical
22
rhBSSL + PlaceboSwedish Orphan BiovitrumPhase 2
51
rhBSSL + PlaceboSwedish Orphan BiovitrumPhase 2
51
alglucosidase alfa + alglucosidase alfaSanofiApproved
84
MyozymeSanofiPhase 2
51
Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved
84
RadiprodilUCBPhase 2
49
Larotrectinib (Vitrakvi, BAY2757556) + Standard of CareBayerPre-clinical
20
Sabril®LundbeckPre-clinical
20
VigabatrinLundbeckApproved
82
NusinersenBiogenPre-clinical
20

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84